Toceranib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Toceranib
Toceranib.svg
Systematic (IUPAC) name
5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
Clinical data
Trade names Palladia
AHFS/Drugs.com International Drug Names
Legal status
Routes Oral
Pharmacokinetic data
Bioavailability 77%
Protein binding 91%-93%
Half-life 16 h
Identifiers
CAS number 356068-94-5
ATCvet code QL01XE91
PubChem CID 8034466
ChemSpider 4486268
UNII 59L7Y0530C YesY
Chemical data
Formula C22H25FN4O2 
Mol. mass 396.46 g/mol
494.46 g/mol (phosphate)

Toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment[1] of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science), toceranib is the only dog-specific anti-cancer drug[2] approved by the U.S. Food and Drug Administration.[3] It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654,[4] a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.

References[edit]

External links[edit]